

1 **Trends and spatial distribution of pneumonia admissions and deaths among**
2 **children <5 years, Uganda, 2013–2021**

3 Mercy Wendy Wanyana^{1*}, Richard Migisha¹, Patrick King¹, Lilian Bulage¹, Benon
4 Kwesiga¹, Daniel Kadobera¹, Alex Rioplexus Ario^{1,2}, Julie R. Harris³

5 ¹Uganda Public Health Fellowship Program, Uganda National Institute of Public Health,
6 Kampala, Uganda

7 ²Ministry of Health, Kampala, Uganda

8 ³US Centers for Disease Control and Prevention, Kampala, Uganda

9

10 ***Correspondence:** Mercy Wendy Wanyana, +256779207928, mwanyana@uniph.go.ug

11 **Target Journal:** BMC Pneumonia

12 Abstract word limit: 350

13 Abstract word count: 333

14 Body word limit: 3500

15 Body word count: 2250

16 Tables limit: 5

17 Tables count: 4

18 Figures limit: 5

19 Figures count: 2

20

21 Abstract

22 **Background:** Pneumonia is the second leading cause of hospital admissions and
23 deaths among children <5 years old in Uganda. In 2013, Uganda adopted various
24 interventions to protect, prevent, and improve the treatment of pneumonia under the
25 Global Action Plan for Prevention and Control of Pneumonia and Diarrhoea (GAPPD),
26 including the introduction of the pneumococcal conjugate vaccine (PCV) into routine
27 immunization schedule. However, little is known about the impact of these interventions
28 on pneumonia admissions and deaths. We described the trends and spatial distribution
29 of pneumonia hospital admissions and mortality among children <5 years in Uganda,
30 2013–2021.

31 **Methods:** We analysed secondary data on pneumonia admissions and deaths from the
32 District Health Information System version 2 during 2013–2021. Reporting rates were
33 calculated as the percentage of expected complete monthly health facility reports
34 submitted to the national surveillance database. The proportion of pneumonia cases
35 admitted and case-fatality rates (CFRs) for children <5 years were calculated for
36 children <5 years presenting at the outpatient department. At national, regional, and
37 district levels, pneumonia mortality rates were calculated per 100,000 children <5 years.
38 The Mann-Kendall Test was used to assess trend significance.

39 **Results:** There were 753,978 pneumonia admissions and 13,632 (2%) deaths during
40 2013–2021. Reporting rates ranged from 78–92%. The overall proportion of pneumonia
41 cases admitted among children <5 years was 23%. The overall CFR was 0.41%, and
42 the overall pneumonia mortality rate among children <5 years was 21 deaths per
43 100,000. From 2013 to 2021, there were declines in the proportion of pneumonia cases
44 admitted (33% to 15%; $p=0.051$), mortality rates (26/100,000 to 13 per 100,000;
45 $p=0.01$), and CFR (0.61% to 0.24%; $p=0.01$), concomitant with increasing PCV
46 coverage. Kotido District had a persistently high proportion of pneumonia cases that
47 were admitted (>30%) every year while Kasese District had persistently high mortality
48 rates (68-150 deaths per 100,000 children <5 years).

49 **Conclusion:** Pneumonia admissions, mortality, and case fatality among children <5
50 years declined during 2013–2021 in Uganda after the introduction of PCV. However,
51 with these trends it is unlikely that Uganda will meet the 2025 GAPPD targets. There is
52 therefore a need to review implementation of existing interventions, identify gaps in
53 order to highlight priority actions to further accelerate declines.

54 **Keywords:** Pneumonia admission, Mortality, Children, Uganda

55

56 **Background**

57 In 2019, pneumonia was the leading infectious cause of death globally among children
58 <5 years old, accounting for 14% of all deaths in this age group¹. Half of the pneumonia
59 cases and deaths among children <5 years are reported in sub-Saharan Africa².

60 Worldwide, pneumonia in childhood is commonly caused by *Streptococcus*
61 *pneumoniae*³. The pneumococcal conjugate vaccine (PCV) contains serotypes that are
62 commonly associated with invasive and mucosal pneumonia among children <5 years
63 and can reduce both incidence and severity of disease⁴. While pneumonia incidence
64 among children <5 years declined globally during 2000 to 2015, the same time period
65 saw an increase in pneumonia requiring admissions in sub-Saharan Africa^{2,5}.

66 In Uganda, pneumonia is the second leading cause of all hospital admissions among
67 children <5 years⁶, most of which is caused by *Streptococcus pneumoniae*⁷. To reduce
68 this burden, Uganda and other low-income countries committed in 2013 to implementing
69 the World Health Organization's integrated Global Action Plan for the Prevention and
70 Control of Pneumonia and Diarrhoea (GAPPD)⁸. This initiative included the introduction
71 of the 10-valent PCV (PCV10) into the routine immunisation schedule. PCV10 targets
72 the commonest pneumococcal serotypes documented in Uganda before its introduction
73 (6B, 19F, and 23F) as well as serotypes 1, 4, 5, 7F, 9V, 14, and 18C^{9,10}. Three doses of
74 PCV10 (PCV1, 2, and 3) are given to children at 6, 10, and 12 weeks of age¹¹. Other
75 low-cost interventions put in place with GAPPD include exclusive breastfeeding for the
76 first six months and continued breastfeeding with appropriate complementary feeding
77 thereafter; use of simple, standardized guidelines for the identification and treatment of
78 pneumonia in the community through integrated community case management of
79 childhood illnesses; and reduction of household air pollution with improved stoves⁸. With
80 these interventions, implemented in 2013, Uganda is attempting to reduce the incidence
81 of pneumonia requiring admission by 75% in children <5 years from 2013 to 2025 and
82 reduce mortality from pneumonia in children <5 years of age to <3 per 1,000 live births
83 by 2025.

84 Currently, little is documented on Uganda's progress towards these goals. Previous
85 studies conducted in Uganda assessed the prevalence of pneumonia at specific

86 timepoints and may not reflect Uganda's progress over time^{12,13}. Additionally, these
87 studies were conducted in sub-regions and may not be generalisable to the entire
88 country or show meaningful spatial differences. We assessed the temporal trends and
89 spatial distribution of pneumonia admissions and mortality among children <5 years in
90 Uganda from 2013–2021 to assess progress towards these goals.

91

92 **Methods**

93 **Study setting**

94 We utilized pneumonia data generated from all health facilities in Uganda. The Uganda
95 health system classifies health facilities into various levels based on their capacities. In
96 Uganda, outpatient pneumonia cases are managed at all levels, while those with
97 pneumonia requiring admission are managed at health centres III and IV, general and
98 regional referral hospitals, and national referral hospitals, all of which have in-patient
99 services¹⁴. Patients are also referred as needed from lower-level facilities (health
100 centres) to higher-level facilities (hospitals).

101 **Data source**

102 We conducted a descriptive study using routinely-collected pneumonia surveillance data
103 from the District Health Information System version 2 (DHIS2) during 2013–2021.
104 DHIS2 is an electronic database that was officially adopted in 2012¹⁵. It contains data
105 on priority diseases, conditions, and events of public health importance, including
106 pneumonia from 2013 to-date¹⁶. Aggregate data on pneumonia cases, admissions, and
107 deaths from both outpatient and inpatient monthly reports (Health Management
108 Information System forms [HMIS] 105 and HMIS 108) from 2013–2021 were used for
109 this study.

110 **Study variables, data management, and analysis**

111 We obtained aggregate data on pneumonia cases and admissions among children <5
112 years to calculate the annual proportion of pneumonia cases admitted. A pneumonia
113 admission was defined as a hospital stay in a person with pneumonia as a primary
114 diagnosis, based on the International Classification of Disease-10 framework. A
115 pneumonia case at the outpatient department was defined as pneumonia as a primary
116 diagnosis based on the International Classification of Disease-10 framework in a patient
117 not requiring a hospital stay. We calculated the proportion of pneumonia cases admitted
118 using pneumonia admissions <5 years as a numerator and total pneumonia cases <5
119 years presenting at the outpatient department as a denominator. (All admitted patients
120 with pneumonia pass through the outpatient department before admission.) Pneumonia

121 deaths were defined as in-patient deaths with pneumonia recorded as the primary
122 cause of death. We calculated pneumonia mortality using pneumonia deaths among
123 children <5 years as a numerator and estimated annual population data for children <5
124 years from the Uganda Bureau of Statistics (UBOS) as a denominator. Case-fatality
125 rates (CFRs) were calculated as the proportion of pneumonia cases <5 years at health
126 facilities who died at the facility. Reporting rates for cases and deaths were calculated
127 as the percentage of the expected monthly reports that were submitted to DHIS2 from
128 2013 to 2021. PCV 3 vaccine coverage was calculated as the percentage of the target
129 population who received 3 doses of the PCV10 in a given year based on data obtained
130 from DHIS2. Although the PCV10 vaccine was introduced in 2013, official rollout to the
131 entire country started in 2014¹⁷. PCV 3 vaccine coverage was therefore calculated from
132 2014 to 2021.

133 We downloaded data in Excel and imported it into EpiInfo 7 software (CDC, Atlanta,
134 USA) for analysis. Annual proportion of pneumonia cases admitted, mortality rates, and
135 case-fatality rates were calculated at national and regional levels. Line graphs were
136 used to describe national and regional trends. The Mann-Kendall test was conducted to
137 assess significance of the trends. Choropleth maps drawn using QGIS software were
138 used to show the spatial distribution of pneumonia admissions and mortality in the
139 country.

140 **Ethical Considerations**

141 Our study utilized routinely generated aggregated surveillance data with no personal
142 identifiers in health facility in-patient monthly reports through the DHIS2. The Ministry of
143 Health (MoH) of Uganda through the office of the Director General Health Services gave
144 approval to access data from the DHIS2. We stored the abstracted data set in a
145 password-protected computer and only shared it with the investigation team. This
146 activity was reviewed by CDC and was conducted consistent with applicable federal law
147 and CDC policy. §

148 §See e.g., 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44
149 U.S.C. §3501 et seq.

150

151

152

153 **Results**

154 **National trends in the proportion of pneumonia cases admitted among children** 155 **<5 years with pneumonia in Uganda, 2013-2021**

156 During the study period, reporting rates for both admissions and deaths increased from
157 78% to 92% (Kendall's score=24, p=0.017). There was a total of 3,560,974 outpatient
158 pneumonia cases and 753,978 admitted pneumonia cases reported among children <5
159 years. The overall proportion of pneumonia cases <5 years admitted was 21% (range:
160 15-34%). Overall, there was a 50% decline in the proportion of pneumonia cases
161 admitted over the study period, from 30% to 15% (Kendall's score=-20, p=0.051),
162 concurrent with increasing PCV 3 vaccine coverage from 60% to 91% (Figure 1).

163 **National trends in pneumonia mortality among children <5 years, Uganda, 2013–** 164 **2021**

165 During the study period, there were 13,632 pneumonia-related deaths among children
166 <5 years. The overall pneumonia mortality rate was 21 deaths per 100,000 children <5
167 years (Figure 2). There was a 50% decline in pneumonia mortality rates from 26 to 13
168 per 100,000 children <5 years (Kendall's score = -14, p=0.005).

169

170 **Pneumonia case-fatality rate among children <5 years, Uganda, 2013–2021**

171 The overall CFR was 0.41% children <5 years with pneumonia (Range: 0.25–0.69).
172 There was a 61% decline from 0.61% to 0.24% over the evaluation period (Kendall's
173 score = -26, p=0.009) (Figure 3).

174 **Regional trends of pneumonia cases admitted, mortality rate and case fatality rate** 175 **among children <5 years, Uganda, 2013-2021**

176 Both the proportion of pneumonia cases admitted and pneumonia mortality rates among
177 children <5 years were higher in the Northern Region than in the Western, Eastern, and

178 Central Regions (Table 1). Case-fatality rates were higher in the Central, Northern, and
179 Western regions than in the Eastern Region. Declines in mortality rates were observed
180 over the study period across all regions, while case-fatality rates declined in the
181 Northern and Western regions (Table 1).

182 **Spatial distribution of proportion of pneumonia cases admitted and mortality**
183 **among children <5 years, Uganda, 2013-2021**

184 Proportion of pneumonia cases among children <5 years that were admitted was
185 generally highest in north-eastern Uganda. Kotido District had consistently high
186 admissions rates of >40% throughout the study period (Figure 4).

187 Kasese District (Figure 5) had consistently high pneumonia mortality throughout the
188 review period ranging from 68 to 150 deaths per 100,000 children <5 years.

189

190 Discussion

191 We described the trends and spatial distribution of pneumonia hospital admissions,
192 mortality, and case-fatality among children <5 years in Uganda from 2013–2021. Over
193 the 9 years, there was a decline in both the proportion of pneumonia cases that were
194 admitted and deaths concomitant with an increase in PCV3 coverage.

195 After the introduction of PCV10 in Uganda in 2013, we found a $\geq 50\%$ reduction in
196 pneumonia cases admitted, mortality, and case-fatality rates among children <5 years
197 over the next 9 years. These findings are in agreement with those in other African
198 countries after PCV was introduced: a study in Burkina Faso identified a 34% reduction
199 in pneumonia admissions among children <5 years five years after the introduction of
200 PCV¹⁸, while another in Zambia found a 38% and 29% decline in pneumonia
201 admissions among children aged <1 year and 1–4 years, respectively, three years after
202 introduction of PCV¹⁹. Studies in South Africa and Rwanda have had similar
203 findings^{20,21}. The greater reductions in our study, compared to the others, could be
204 related to the longer period of observation after the introduction of PCV in our study.
205 Declines in admissions and case fatality rates observed in 2015 could also be
206 attributable to the impact of the WHO-recommended admission criteria introduced in
207 2014²². Before 2014, any child <5 years old with pneumonia (i.e., with fast breathing
208 and/or chest indrawing) was recommended to be admitted. With the revisions in 2014,
209 recommendations for admission were changed to pneumonia plus any danger signs,
210 which would have led to declines in admissions. The revised treatment guidelines
211 promoted outpatient treatment of pneumonia without danger signs with oral amoxicillin.
212 This was a more effective and accessible treatment, and has been linked to a reduction
213 in pneumonia deaths among children²².

214 We noted that the largest decline in case-fatality rates occurred from 2015 to 2016. It is
215 unknown why this occurred, but it may be related to the 32% decline in new HIV
216 infections between 2014 and 2015, which represented the largest decline in many
217 years²⁶. HIV is a key risk factor for pneumonia deaths among children <5 years linked
218 and is associated with a 4-fold increased risk of pneumonia death²⁷. Additional declines
219 in pneumonia case-fatality rates even after 2015 might also reflect improvements in the

220 quality of healthcare during the study period. Integrated community case management
221 introduced at the start of the review period facilitated prompt diagnosis and access to
222 antibiotics at the community level, improving appropriate care-seeking²³. During the
223 review period, there were also increases in access to electricity (both hydroelectricity
224 and solar), especially at low-level health facilities over time, there is increased access to
225 oxygen therapy thereby improving patient survival thus reducing case-fatality rates^{24,25}.

226 The 50% decline in pneumonia admissions over the 9-year period was borderline
227 significant, suggesting a smaller effect of the PCV on pneumonia admissions than on
228 mortality or case-fatality²⁸. While PCV reduces the severity and incidence of pneumonia
229 among the strains it targets²⁹, previous studies have shown that the introduction of PCV
230 can lead to an increase in the proportion of pneumococcal pneumonia due to non-
231 vaccine pneumococcal serotypes^{30,31}. It is possible that in Uganda, like other African
232 countries, other serotypes are taking the place of those targeted by PCV. A study in the
233 Gambia indicated a 47% increase in pneumococcal pneumonia due to non-vaccine
234 serotypes 3 years following PCV13 introduction³². Similarly, a 27% increase in
235 pneumococcal pneumonia was observed in Botswana following introduction of PCV³³.
236 However, there are few data available on the current distribution of circulating serotypes
237 in Uganda. The decline suggests that Uganda may be on track to reach the GAPPD
238 target of a 75% reduction in admissions by 2025. Nonetheless, monitoring of trends in
239 the circulating pneumococcal serotypes in the post-PCV era and maintaining other
240 interventions to reduce the burden and impact of childhood pneumonia is important to
241 ensuring that the reductions continue³⁴.

242 Regional variations in the proportion of pneumonia cases admitted, pneumonia
243 mortality, and case-fatality rates were observed. The highest proportion of pneumonia
244 cases admitted and mortality were observed in the northern and eastern regions. These
245 regions are characterised with higher levels of poverty and poor housing compared to
246 other areas of the country, which are known to be associated with increased likelihood
247 of pneumonia requiring admission and mortality^{35,36}. There is a need to understand the
248 factors associated with high burden of severe pneumonia in these regions to develop
249 targeted interventions.

250 Our findings should be interpreted with the following limitations. We used inpatient data,
251 which could lead to underestimation of the true pneumonia mortality by missing cases
252 and deaths that occurred in communities. Secondly, we used aggregated secondary
253 data, which lacked key variables to further explore trends across subcategories within
254 this age group. Thirdly, we were unable to make before-and-after PCV10 comparisons
255 of pneumonia admissions and deaths due to the lack of data before PCV10 introduction.
256 As a result, we cannot assess the impact of the introduction of PCV10 on the observed
257 trends of pneumonia admissions and deaths to the interventions introduced in 2013.
258 Finally, despite reductions in pneumonia admissions and deaths with increasing PCV10
259 coverage, we cannot definitively attribute these reductions to PCV10. During this time
260 period, other interventions, including exclusive breastfeeding for the first six months and
261 continued breastfeeding with appropriate complementary feeding thereafter, increased
262 access to antibiotics through integrated community case management of childhood
263 illnesses, reduction of household air pollution with improved stoves, and increased
264 access to oxygen therapy were implemented, and these also likely led to reductions.

265

266 **Conclusion**

267 Our findings demonstrate declines in pneumonia admissions, mortality rates, and case-
268 fatality rates among children <5 years over the 9-year period following the introduction
269 of PCV in Uganda. However, with these trends it is unlikely that Uganda will meet the
270 2025 targets. Reviewing the implementation of existing interventions and identification
271 of gaps to highlight priority actions could further accelerate decline.

272 **List of abbreviations**

273 **DHIS2:** District Health Information System version 2

274 **GAPPD:** Global Action Plan for the Prevention and Control of Pneumonia and
275 Diarrhoea

276 **HC:** Health Centre

277 **HMIS:** Health Management Information System

278 **PCV:** Pneumococcal Conjugate Vaccine

279 **UBOS:** Uganda Bureau of Statistics

280

281 **Acknowledgements**

282 We would like to thank the Ministry of Health for providing access to DHIS2 data that
283 was used for this analysis. We appreciate the technical support provided by the Division
284 of Surveillance, Information and Knowledge Management, MoH. Finally, we thank the
285 US-CDC for supporting the activities of the Uganda Public Health Fellowship Program.

286

287 References

- 288 1. Perin J, Mulick A, Yeung D, Villavicencio F, Lopez G, Strong KL, et al. Global,
289 regional, and national causes of under-5 mortality in 2000-19: an updated
290 systematic analysis with implications for the Sustainable Development Goals.
291 *Lancet Child Adolesc Heal*. 2022 Feb;6(2):106–15.
- 292 2. Troeger CE, Khalil IA, Blacker BF, Biehl MH, Albertson SB, Zimsen SRM, et al.
293 Quantifying risks and interventions that have affected the burden of lower
294 respiratory infections among children younger than 5 years: an analysis for the
295 Global Burden of Disease Study 2017. *Lancet Infect Dis* [Internet]. 2020 Jan
296 1;20(1):60–79. Available from: [https://doi.org/10.1016/S1473-3099\(19\)30410-4](https://doi.org/10.1016/S1473-3099(19)30410-4)
- 297 3. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al.
298 Burden of disease caused by *Streptococcus pneumoniae* in children younger than
299 5 years: global estimates. *Lancet* (London, England). 2009 Sep;374(9693):893–
300 902.
- 301 4. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal
302 serogroups cause the most invasive disease: implications for conjugate vaccine
303 formulation and use, part I. *Clin Infect Dis an Off Publ Infect Dis Soc Am*. 2000
304 Jan;30(1):100–21.
- 305 5. McAllister DA, Liu L, Shi T, Chu Y, Reed C, Burrows J, et al. Global, regional, and
306 national estimates of pneumonia morbidity and mortality in children younger than
307 5 years between 2000 and 2015: a systematic analysis. *Lancet Glob Heal*. 2019
308 Jan;7(1):e47–57.
- 309 6. MoH M of HU. Ministry of Health Annual Sector Performance Report 2020/2021
310 [Internet]. Kampala, Uganda; 2021. Available from:
311 [http://library.health.go.ug/publications/performance-management/annual-health-](http://library.health.go.ug/publications/performance-management/annual-health-sector-performance-report-financial-year-202021)
312 [sector-performance-report-financial-year-202021](http://library.health.go.ug/publications/performance-management/annual-health-sector-performance-report-financial-year-202021)
- 313 7. Nantanda R, Hildenwall H, Peterson S, Kaddu-Mulindwa D, Kalyesubula I,
314 Tumwine JK. Bacterial aetiology and outcome in children with severe pneumonia
315 in Uganda. *Ann Trop Paediatr*. 2008 Dec;28(4):253–60.
- 316 8. WHO (World Health Organisation). Ending preventable child deaths from
317 pneumonia and diarrhoea by 2025: the integrated global action plan for
318 pneumonia and diarrhoea (GAPPD). 2013;
- 319 9. Lindstrand A, Kalyango J, Alfvén T, Darenberg J, Kadobera D, Bwanga F, et al.
320 Pneumococcal Carriage in Children under Five Years in Uganda-Will Present
321 Pneumococcal Conjugate Vaccines Be Appropriate? *PLoS One*.
322 2016;11(11):e0166018.
- 323 10. Nackers F, Cohuet S, le Polain de Waroux O, Langendorf C, Nyehangane D,
324 Ndazima D, et al. Carriage prevalence and serotype distribution of *Streptococcus*
325 *pneumoniae* prior to 10-valent pneumococcal vaccine introduction: A population-
326 based cross-sectional study in South Western Uganda, 2014. *Vaccine* [Internet].
327 2017;35(39):5271–7. Available from:

- 328 <https://www.sciencedirect.com/science/article/pii/S0264410X17310071>
- 329 11. MoH (Ministry of Health Uganda). Routine Immunisation Question and Answer
330 Booklet [Internet]. Kampala, Uganda; 2013. Available from:
331 [https://www.unicef.org/uganda/media/2776/file/Routine Immunisation Q & A](https://www.unicef.org/uganda/media/2776/file/Routine%20Immunisation%20Q%20&%20A%20booklet.pdf)
332 [booklet.pdf](https://www.unicef.org/uganda/media/2776/file/Routine Immunisation Q & A booklet.pdf)
- 333 12. Kiconco G, Turyasiima M, Ndamira A, Yamile OA, Egesa WI, Ndiwimana M, et al.
334 Prevalence and associated factors of pneumonia among under-fives with acute
335 respiratory symptoms: a cross sectional study at a Teaching Hospital in Bushenyi
336 District, Western Uganda. *Afr Health Sci*. 2021 Dec;21(4):1701–10.
- 337 13. Ma C, Gunaratnam LC, Ericson A, Conroy AL, Namasopo S, Opoka RO, et al.
338 Handheld Point-of-Care Lactate Measurement at Admission Predicts Mortality in
339 Ugandan Children Hospitalized with Pneumonia: A Prospective Cohort Study. *Am*
340 *J Trop Med Hyg*. 2019 Jan;100(1):37–42.
- 341 14. IHE (Institute for Health Metrics and Evaluation). Assessing Facility Capacity,
342 Costs of Care, and Patient Perspectives [Internet]. Seattle; Available from:
343 [https://www.healthdata.org/sites/default/files/files/policy_report/2014/ABCE/Uganda](https://www.healthdata.org/sites/default/files/files/policy_report/2014/ABCE/Uganda/ABCE_Uganda_full_report_2014.pdf)
344 [a/ABCE_Uganda_full_report_2014.pdf](https://www.healthdata.org/sites/default/files/files/policy_report/2014/ABCE/Uganda/ABCE_Uganda_full_report_2014.pdf)
- 345 15. Kiberu VM, Matovu JKB, Makumbi F, Kyoziira C, Mukooyo E, Wanyenze RK.
346 Strengthening district-based health reporting through the district health
347 management information software system: the Ugandan experience. *BMC Med*
348 *Inform Decis Mak* [Internet]. 2014;14(1):40. Available from:
349 <https://doi.org/10.1186/1472-6947-14-40>
- 350 16. MoH (Ministry of Health Uganda). National Technical Guidelines for Integrated
351 Disease Surveillance and Response Third Edition [Internet]. 2021. Available from:
352 [https://www.afro.who.int/sites/default/files/2021-09/2_Uganda 3rd IDSR Tech](https://www.afro.who.int/sites/default/files/2021-09/2_Uganda%203rd%20IDSR%20Tech%20Guideline_PrintVersion_10Sep2021.pdf)
353 [Guideline_PrintVersion_10Sep2021.pdf](https://www.afro.who.int/sites/default/files/2021-09/2_Uganda 3rd IDSR Tech Guideline_PrintVersion_10Sep2021.pdf)
- 354 17. WHO (World Health Organisation). Uganda rolls out the Pneumococcal Conjugate
355 Vaccine (PCV) [Internet]. 2014 [cited 2023 Dec 2]. Available from:
356 [https://www.afro.who.int/news/uganda-rolls-out-pneumococcal-conjugate-vaccine-](https://www.afro.who.int/news/uganda-rolls-out-pneumococcal-conjugate-vaccine-pcv)
357 [pcv](https://www.afro.who.int/news/uganda-rolls-out-pneumococcal-conjugate-vaccine-pcv)
- 358 18. Kaboré L, Ouattara S, Sawadogo F, Gervaix A, Galetto-Lacour A, Karama R, et
359 al. Impact of 13-valent pneumococcal conjugate vaccine on the incidence of
360 hospitalizations for all-cause pneumonia among children aged less than 5 years in
361 Burkina Faso: An interrupted time-series analysis. *Int J Infect Dis* [Internet]. 2020
362 Jul 1;96:31–8. Available from: <https://doi.org/10.1016/j.ijid.2020.03.051>
- 363 19. Mpabalwani EM, Lukwesa-Musyani C, Imamba A, Nakazwe R, Matapo B,
364 Muzongwe CM, et al. Declines in Pneumonia and Meningitis Hospitalizations in
365 Children Under 5 Years of Age After Introduction of 10-Valent Pneumococcal
366 Conjugate Vaccine in Zambia, 2010–2016. *Clin Infect Dis* [Internet]. 2019 Sep
367 5;69(Supplement_2):S58–65. Available from: <https://doi.org/10.1093/cid/ciz456>
- 368 20. Kleynhans J, Tempia S, Shioda K, von Gottberg A, Weinberger DM, Cohen C.

- 369 Estimated impact of the pneumococcal conjugate vaccine on pneumonia mortality
370 in South Africa, 1999 through 2016: An ecological modelling study. *PLOS Med*
371 [Internet]. 2021 Feb 16;18(2):e1003537. Available from:
372 <https://doi.org/10.1371/journal.pmed.1003537>
- 373 21. Rurangwa J, Rujeni N. Decline in Child Hospitalization and Mortality After the
374 Introduction of the 7-Valent Pneumococcal Conjugative Vaccine in Rwanda. *Am*
375 *J Trop Med Hyg*. 2016 Sep;95(3):680–2.
- 376 22. WHO (World Health Organisation). Revised who classification and treatment of
377 childhood pneumonia at health facilities, 2014. Geneva WHO. 2021;
- 378 23. Kalyango JN, Alfvén T, Peterson S, Mugenyi K, Karamagi C, Rutebemberwa E.
379 Integrated community case management of malaria and pneumonia increases
380 prompt and appropriate treatment for pneumonia symptoms in children under five
381 years in Eastern Uganda. *Malar J* [Internet]. 2013;12(1):340. Available from:
382 <https://doi.org/10.1186/1475-2875-12-340>
- 383 24. Khogali A, Ahmed A, Ibrahim M, Karrar K, Elsheikh M, Abdelraheem E, et al.
384 Building power-ful health systems: the impacts of electrification on health
385 outcomes in LMICs. *Psychol Health Med* [Internet]. 2022 Dec 15;27(sup1):124–
386 37. Available from: <https://doi.org/10.1080/13548506.2022.2109049>
- 387 25. Turnbull H, Conroy A, Opoka RO, Namasopo S, Kain KC, Hawkes M. Solar-
388 powered oxygen delivery: proof of concept. *Int J Tuberc lung Dis Off J Int Union*
389 *against Tuberc Lung Dis*. 2016 May;20(5):696–703.
- 390 26. Uganda AIDS Commission. The Uganda HIV and AIDS country progress report
391 July 2015-June 2016.
- 392 27. Wilkes C, Bava M, Graham HR, Duke T. What are the risk factors for death
393 among children with pneumonia in low- and middle-income countries? A
394 systematic review. *J Glob Health*. 2023 Feb;13:5003.
- 395 28. Hackshaw A, Kirkwood A. Interpreting and reporting clinical trials with results of
396 borderline significance. *BMJ* [Internet]. 2011 Jul 4;343:d3340. Available from:
397 <http://www.bmj.com/content/343/bmj.d3340.abstract>
- 398 29. Reyburn R, Tsatsaronis A, von Mollendorf C, Mulholland K, Russell FM.
399 Systematic review on the impact of the pneumococcal conjugate vaccine ten
400 valent (PCV10) or thirteen valent (PCV13) on all-cause, radiologically confirmed
401 and severe pneumonia hospitalisation rates and pneumonia mortality in children
402 0-9 years old. *J Glob Health*. 2023 Feb;13:5002.
- 403 30. Masomian M, Ahmad Z, Gew LT, Poh CL. Development of Next Generation
404 *Streptococcus pneumoniae* Vaccines Conferring Broad Protection. *Vaccines*.
405 2020 Mar;8(1).
- 406 31. Ali MA, Okojokuw OJ, Adiekwuo RC, Robinson JW. Prevalence and serotypes of
407 *Streptococcus pneumoniae* among under five children attending Toro general
408 hospital, Bauchi State, Nigeria. *Microbes Infect Dis* [Internet]. 2023;4(2):468–76.

- 409 Available from: https://mid.journals.ekb.eg/article_240662.html
- 410 32. Mackenzie GA, Hill PC, Jeffries DJ, Hossain I, Uchendu U, Ameh D, et al. Effect
411 of the introduction of pneumococcal conjugate vaccination on invasive
412 pneumococcal disease in The Gambia: a population-based surveillance study.
413 *Lancet Infect Dis.* 2016 Jun;16(6):703–11.
- 414 33. Patel SM, Shaik-Dasthagirisaheb YB, Congdon M, Young RR, Patel MZ, Mazhani
415 T, et al. Evolution of pneumococcal serotype epidemiology in Botswana following
416 introduction of 13-valent pneumococcal conjugate vaccine. *PLoS One.*
417 2022;17(1):e0262225.
- 418 34. Du Q, Shi W, Yu D, Yao K. Epidemiology of non-vaccine serotypes of
419 *Streptococcus pneumoniae* before and after universal administration of
420 pneumococcal conjugate vaccines. *Hum Vaccin Immunother [Internet].* 2021 Dec
421 2;17(12):5628–37. Available from:
422 <https://doi.org/10.1080/21645515.2021.1985353>
- 423 35. Atamanov A, Malasquez Carbonel EA, Masaki T, Myers CA, Granguillhome
424 Ochoa R, Sinha N. Uganda Poverty Assessment: Strengthening Resilience to
425 Accelerate Poverty Reduction. 2022;
- 426 36. Azab SFAH, Sherief LM, Saleh SH, Elsaheed WF, Elshafie MA, Abdelsalam SM.
427 Impact of the socioeconomic status on the severity and outcome of community-
428 acquired pneumonia among Egyptian children: a cohort study. *Infect Dis Poverty*
429 *[Internet].* 2014;3(1):14. Available from: <https://doi.org/10.1186/2049-9957-3-14>
- 430




Figure 1: National trend in proportion of pneumonia cases admitted among children <5 years with pneumonia, Uganda, 2013–2021; PCV: Pneumococcal conjugate vaccine. Data for 2013 were not available.





Figure 2: National trend in pneumonia mortality among children <5 years, Uganda, 2013–2021; PCV: Pneumococcal conjugate vaccine. Data for 2013 were not available.



medRxiv preprint doi: <https://doi.org/10.1101/2024.02.13.24302770>; this version posted February 14, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This preprint is not certified by peer review. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Figure 3: Trends in pneumonia case-fatality rate among children <5 years, Uganda, 2013-2021




Figure 4: Spatial distribution of proportion of pneumonia cases admitted among children <5 years, 2013-2021, Uganda




Figure 5: Spatial distribution of pneumonia mortality rate among children <5 years, 2013-2021, Uganda

Table 1: Regional trends of pneumonia cases admitted, mortality rate, and case fatality rate among children <5 years Uganda, 2013-2021. Kendall's score and p-value represents the presence or absence of a 9-year linear trend.

Region	Proportion of pneumonia cases admitted (%) children <5 years			Case-fatality rate %			Mortality rate Per 100,000 children <5 years		
	Annual Mean	Kendall's Score	P-value	Annual Mean	Kendall's Score	P-value	Annual Mean	Kendall's Score	P-value
Central	14.0	-4	0.70	0.49	-5	0.55	19	-18	0.03
Eastern	10.7	-11	0.71	0.33	-11	0.13	15	-20	0.05
Northern	28.8	1	0.99	0.49	-15	0.04	28	-30	0.003
Western	21.3	-5	0.56	0.44	-15	0.04	21	-26	0.009

medRxiv preprint doi: <https://doi.org/10.1101/2024.02.13.24302770>; this version posted February 14, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

medRxiv preprint doi: <https://doi.org/10.1101/2024.02.13.24302770>; this version posted February 14, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.